Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HTMC0435 tablets in advanced pancreatic cancer (Phase II)
CTR20230616Phase 2Active
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HTMC0435 in pancreatic cancer (PC), sponsored by Shanghai Huilun Pharmaceutical Co., Ltd.. Started Oct 2023; status: active.
02
Drugs
HTMC0435
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20230616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230616.